FamiCord opens its first laboratory outside Europe in Dubai.

For the first time, the Group is storing more than one million umbilical cord blood units and other biological materials.

FamiCordTx in Warsaw manufactures the first proprietary CAR-T product for cancer therapy.

Following the merger, the Group consolidates its overlapping activities in Spain and Switzerland.

PBKM FamiCord acquires the SmartCells Group, which operates in the UK, the Middle East and Hong Kong.

Vita 34 and PBKM FamiCord merge to form the largest european stem cell bank. Vita 34 AG will become the sole owner of PBKM S.A. and PBKM shareholders receive Vita 34 shares in exchange for PBKM shares.

AOC Health GmbH becomes the main shareholder of PBKM.

FamiCordTx is founded as a PBKM spin-off to develop CAR-T therapies for the treatment of cancer.

PBKM strengthens its presence in Turkey with a further acquisition and begins strategic cooperation with Acibadem, the country’s largest hospital group.

PBKM acquires a stake in Sorgente, the market leader on the Italian market.

Sevibe, the Spanish subsidiary of the PBKM FamiCord Group, acquires local competitor IVI Cordon.

PBKM acts as a backup for a stem cell bank in Switzerland and transfers its stem cells safely from Belgium, Switzerland and Germany to Warsaw for storage.

PBKM FamiCord launches an Expanded Access Program for the use of umbilical cord blood for brain repair.

PBKM FamiCord’s services will also be available in the Balkans in cooperation with BioSave.

PBKM acquires Stemlab, the market leader in Portugal, which also operates in Italy, Spain and Switzerland.

PBKM acquires a laboratory in Switzerland.

The PBKM FamiCord Group has grown to become the world’s fifth largest umbilical cord blood bank.

Vita 34 acquires the largest German competitor Seracell and thus becomes the clear market leader.

PBKM goes public as Polski Bank Komórek Macierzystych S.A. on the Warsaw Stock Exchange.

Sevibe Cells’ laboratory becomes the first private stem cell bank in Spain to be accredited by the AABB.

Vita 34 acquires Stemcare, the largest private umbilical cord blood bank in Denmark.

Vita 34 is expanding via partnerships and minority shareholdings in the Balkans and the Baltic States.

Following further acquisitions, the PBKM FamiCord Group stores 122,000 umbilical cord blood and tissue samples.

PBKM acquires majority stakes in local competitors in Poland.

PBKM acquires Yasam Bankasi, the oldest umbilical cord blood bank in Turkey.

In Warsaw, PBKM opens the most modern site for the processing and storage of stem cells in Europe.

PBKM acquires a blood bank in New Jersey, USA with 1,800 preparations for allogeneic applications.

The first stem cell transplant from umbilical cord blood is performed in Hungary.

The first therapy with PBKM mesenchymal stem cells is carried out in Poland.

Enterprise Investors invests in PBKM with a venture fund.

PBKM FamiCord has stored more than 35,0000 umbilical cord blood and tissue samples.

PBKM launches FamiCord as a common brand for all European activities.

PBKM founds the joint venture in Romania (Biogenis) and FamiCord Italia.

PBKM acquires the umbilical cord blood and sperm bank Krio Intezet in Hungary.

Vita 34 AG goes public and is listed on the regulated market of the Frankfurt Stock Exchange and at the same time in the Prime Standard sub-segment.

The first stem cell application with umbilical cord blood from the PBKM laboratory is carried out.

PBKM receives approval to operate a tissue and cell bank in accordance with the Polish Transplantation Act and also receives the internationally recognized AABB accreditation.

PBKM makes its first international acquisition in Latvia and acquires a minority stake in an umbilical cord blood bank in Spain.

Vita 34 receives approval for the production of blood samples for allogeneic use and can now also work as a public blood bank.

PBKM secures further financing from a business angel investor and continues to expand the laboratory.

For the first time, Vita 34 successfully uses stored umbilical cord blood to treat a sibling suffering from lymphoblastic leukemia (allogeneic application).

PBKM expands its activities throughout Poland and becomes the market leader in the country.

PBKM is audited by the Institute of Hematology and Transfusion Medicine.

Vita 34 moves into its current company headquarters in Bio City Leipzig and opens up the “Glass Laboratory” to give customers an insight into its own work.

In Warsaw, PBKM commences operations under the name Polski Bank Komórek Macierzystych Sp. z o.o. (Polish Stem Cell Bank) and sets up its first laboratory at the Children’s Memorial Health Institute.